research BH31 Ritlecitinib for severe alopecia areata: does regional prescribing match national guidance?
This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.
